Atrophic dermatofibrosarcoma protuberans: report of a case demonstrated by detecting COL1A1-PDGFB rearrangement

Diagnostic Pathology

Hong Fang¹  Dolores López-Terrada²  Kayuri U Patel²  Jianjun Qiao¹ 

[1] Department of Dermatology, The First Affiliated Hospital, College of Medicine, Zhejiang University, No. 79, Qingchun Road, Hangzhou, 310003, People’s Republic of China;Department of Pathology, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX, 77030, USA

关键词: Sarcoma;    Atrophic;    CD34;    COL1A1-PDGFB;    Dermatofibrosarcoma protuberans;   

Others  :  807812
DOI  :  10.1186/1746-1596-7-166

 received in 2012-08-28, accepted in 2012-11-22,  发布年份 2012

【 摘 要 】

Dermatofibrosarcoma protuberans is a locally aggressive mesenchymal neoplasm. It usually presents as an indurated plaque that protrudes above the surface of the skin. Some patients have clinically persistent plaques that might be atrophic. The atrophic variant of dermatofibrosarcoma protuberans may be confused with some common skin diseases with atrophic appearance. We reported a 40-year-old woman who had a 10-year history of an atrophic dermatofibrosarcoma protuberans. Molecular analysis showed a fusion between COL1A1 exon 31 to exon 2 of PDGFB. The lesion was totally excised, with negative margins of the resection demonstrated by CD34 immunostaining. To our knowledge, this is the second case of atrophic dermatofibrosarcoma protuberans confirmed by detection of COL1A1-PDGFB fusion gene. This appears to be the first report of a fusion between COL1A1 exon 31 to exon 2 of PDGFB in atrophic dermatofibrosarcoma protuberans.

Virtual slides

The virtual slides for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1249657688795311 webcite

【 授权许可】

   
2012 Qiao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Dimitropoulos VA: Dermatofibrosarcoma protuberans. Dermatol Ther 2008, 21:428-432.
• [2]Kampshoff JL, Cogbill TH: Unusual skin tumors: Merkel cell carcinoma, eccrine carcinoma, glomus tumors, and dermatofibrosarcoma protuberans. Surg Clin North Am 2009, 89:727-738.
• [3]Sinovich V, Hollowood K, Burge S: Atrophic dermatofibrosarcoma protuberans. Australas J Dermatol 2005, 46:114-117.
• [4]Sheehan DJ, Madkan V, Strickling WA, Peterson CM: Atrophic dermatofibrosarcoma protuberans: a case report and reappraisal of the literature. Cutis 2004, 74:237-242.
• [5]Young CR 3rd, Albertini MJ: Atrophic dermatofibrosarcoma protuberans: case report, review, and proposed molecular mechanisms. J Am Acad Dermatol 2003, 49:761-764.
• [6]Bogucki B, Neuhaus I, Hurst EA: Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg 2012. 10.1111/j.1524-4725.2011.02292.x.
• [7]Llombart B, Sanmartin O, Requena C, Monteagudo C, Botella-Estrada R, Nagore E, Serra C, Alfaro A, Pellin A, Llombart-Bosch A, et al.: Atrophic dermatofibrosarcoma protuberans with the fusion gene COL1A1-PDGFB. J Eur Acad Dermatol Venereol 2008, 22:371-374.
• [8]Hanabusa M, Kamo R, Harada T, Ishii M: Dermatofibrosarcoma protuberans with atrophic appearance at early stage of the tumor. J Dermatol 2007, 34:336-339.
• [9]Martin L, Piette F, Blanc P, Mortier L, Avril MF, Delaunay MM, Dreno B, Granel F, Mantoux F, Aubin F, et al.: Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. Br J Dermatol 2005, 153:932-936.
• [10]Fujimoto M, Kikuchi K, Okochi H, Furue M: Atrophic dermatofibrosarcoma protuberans: a case report and review of the literature. Dermatology 1998, 196:422-424.
• [11]Wu JK, Malik MM, Egan CA: Atrophic dermatofibrosarcoma protuberans: an uncommon and misleading variant. Australas J Dermatol 2004, 45:175-177.
• [12]Grayson W, Pantanowitz L: Histological variants of cutaneous Kaposi sarcoma. Diagn Pathol 2008, 3:31. BioMed Central Full Text
• [13]Martorell M, Perez-Valles A, Gozalbo F, Garcia-Garcia JA, Gutierrez J, Gaona J: Solitary fibrous tumor of the thigh with epithelioid features: a case report. Diagn Pathol 2007, 2:19. BioMed Central Full Text
• [14]Hollmig ST, Sachdev R, Cockerell CJ, Posten W, Chiang M, Kim J: Spindle cell neoplasms encountered in dermatologic surgery: a review. Dermatol Surg 2012, 38:825-850.
• [15]Rodriguez-Jurado R, Palacios C, Duran-McKinster C, Mercadillo P, Orozco-Covarrubias L, Saez-de-Ocariz Mdel M, Ruiz-Maldonado R: Medallion-like dermal dendrocyte hamartoma: a new clinically and histopathologically distinct lesion. J Am Acad Dermatol 2004, 51:359-363.
• [16]Marque M, Bessis D, Pedeutour F, Viseux V, Guillot B, Fraitag-Spinner S: Medallion-like dermal dendrocyte hamartoma: the main diagnostic pitfall is congenital atrophic dermatofibrosarcoma. Br J Dermatol 2009, 160:190-193.
• [17]Ducharme EE, Baribault KE, Husain S, Engler DE: Medallion-like dermal dendrocyte hamartoma in a 36-year-old male. J Am Acad Dermatol 2008, 59:169-172.
• [18]Patel KU, Szabo SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, Lopez-Terrada D: Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol 2008, 39:184-193.
• [19]Maire G, Fraitag S, Galmiche L, Keslair F, Ebran N, Terrier-Lacombe MJ, de Prost Y, Pedeutour F: A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 2007, 143:203-210.
• [20]Lemm D, Mugge LO, Mentzel T, Hoffken K: Current treatment options in dermatofibrosarcoma protuberans. J Cancer Res Clin Oncol 2009, 135:653-665.
• [21]Paradisi A, Abeni D, Rusciani A, Cigna E, Wolter M, Scuderi N, Rusciani L, Kaufmann R, Podda M: Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery. Cancer Treat Rev 2008, 34:728-736.
• [22]Galimberti G, Montano AP, Kowalczuk A, Ferrario D, Galimberti R: Outcomes in 11 patients with dermatofibrosarcoma protuberans treated with Mohs micrographic surgery. Int J Dermatol 2012, 51:89-93.
• [23]Tan WP, Barlow RJ, Robson A, Kurwa HA, McKenna J, Mallipeddi R: Dermatofibrosarcoma protuberans: 35 patients treated with Mohs micrographic surgery using paraffin sections. Br J Dermatol 2011, 164:363-366.
• [24]McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005, 23:866-873.
• [25]Rutkowski P, Wozniak A, Switaj T: Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma 2011, 2011:959132.
• [26]Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-3591.
• [27]Rutkowski P, Debiec-Rychter M, Nowecki Z, Michej W, Symonides M, Ptaszynski K, Ruka W: Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011, 25:264-270.
• [28]Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, et al.: Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1779.